Comparative Pharmacology
Head-to-head clinical analysis: IOHEXOL versus RENO 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOHEXOL versus RENO 60.
IOHEXOL vs RENO-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ionic, water-soluble, iodinated contrast agent that increases the radiopacity of vascular structures and body cavities, allowing visualization during radiographic procedures. It does not bind to serum proteins and is rapidly distributed in extracellular fluid.
RENO-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality iodinated contrast agent. It attenuates X-rays by blocking photons due to the high atomic number of iodine, thereby enhancing vascular and tissue contrast. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Intravenous: 300-370 mg iodine/kg (0.3-0.37 mL/kg of 300 mg I/mL solution) for contrast imaging; typical range 15-150 mL per procedure depending on examination. Intra-arterial: Doses vary by procedure, typically 1-10 mL total. Do not exceed 3 mL/kg total dose.
Intravenous administration of 0.5-1.0 mL/kg (up to 150 mL total) per radiographic procedure. Dose may be repeated once if needed.
None Documented
None Documented
Clinical Note
moderateIohexol + Metformin
"The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin."
Terminal elimination half-life approximately 2-3 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 30-60 hours, necessitating dose adjustment or avoidance.
Terminal elimination half-life approximately 30-60 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Primarily renal via glomerular filtration; 90-100% of administered dose excreted unchanged in urine within 24 hours. Less than 2% excreted in feces. Biliary excretion negligible (<1%).
Primarily renal excretion via glomerular filtration; up to 20% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent